Cidara Therapeutics, Inc.

Informe acción NasdaqCM:CDTX

Capitalización de mercado: US$123.0m

Salud financiera de hoja de balance de Cidara Therapeutics

Salud financiera controles de criterios 6/6

Cidara Therapeutics tiene un patrimonio de los accionistas total de $115.6M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $162.3M y $46.7M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$127.39m
PatrimonioUS$115.63m
Total pasivoUS$46.70m
Activos totalesUS$162.33m

Actualizaciones recientes sobre salud financiera

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14
We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14
We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara spikes on $11M milestone payment from partner Mundipharma

Oct 04

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Sep 13

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17
Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17
Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04
Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($156.8M) de CDTX superan a sus pasivos a corto plazo ($44.3M).

Pasivo a largo plazo: Los activos a corto plazo de CDTX ($156.8M) superan a sus pasivos a largo plazo ($2.4M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: CDTX está libre de deudas.

Reducción de la deuda: CDTX no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 20.3%.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CDTX tiene suficiente cash runway para 10 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que CDTX disponga de suficiente cash runway para 12 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.


Descubre empresas con salud financiera